



May 6, 2014

## **Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2014 Financial Results on May 13, 2014**

SAN DIEGO, May 6, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 13, 2014, at 5:00 p.m. EDT to report its first quarter 2014 financial results and to provide a corporate update.

In order to participate in the conference call, please dial 1-877-303-6235 (domestic) or 1-631-291-4837 (international) and refer to conference ID 35782307. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at [www.fatetherapeutics.com](http://www.fatetherapeutics.com). The archived webcast will be available on the Company's website beginning approximately two hours after the event.

### **About Fate Therapeutics, Inc.**

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases. The Company utilizes established pharmacologic modalities, including small molecules and therapeutic proteins, and well-characterized biological mechanisms to enhance the therapeutic potential of adult stem cells. The Company has built two adult stem cell modulation platforms: a hematopoietic stem cell (HSC) modulation platform, which seeks to optimize the therapeutic potential of HSCs for treating patients with hematologic malignancies and rare genetic disorders, and a muscle satellite stem cell modulation platform, which seeks to activate the regenerative capacity of muscle for treating patients with degenerative muscle disorders. The Company is presently advancing its lead product candidate, PROHEMA<sup>®</sup>, a pharmacologically-modulated HSC therapeutic, in Phase 2 clinical development for hematologic malignancies. Fate Therapeutics is also advancing its proprietary Wnt7a protein analogs in preclinical development for the treatment of muscular dystrophies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit [www.fatetherapeutics.com](http://www.fatetherapeutics.com).

CONTACT: Paul Cox, Stern Investor Relations, Inc.

212.362.1200, [paul@sternir.com](mailto:paul@sternir.com)